Previous close | 7.8000 |
Open | 1.2000 |
Bid | 0.2000 |
Ask | 0.3500 |
Strike | 230.00 |
Expiry date | 2024-05-17 |
Day's range | 0.3400 - 1.9000 |
Contract range | N/A |
Volume | |
Open interest | 5 |
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?
Biogen stock jumped early Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.